167 related articles for article (PubMed ID: 32293341)
1. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
Dai WF; Beca JM; Croxford R; Isaranawatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Hanna TP; Chan KKW
BMC Cancer; 2020 Apr; 20(1):304. PubMed ID: 32293341
[TBL] [Abstract][Full Text] [Related]
2. Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
Dai WF; Beca J; Croxford R; Isaranuwatchai W; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
Int J Cancer; 2021 Apr; 148(8):1910-1918. PubMed ID: 33105030
[TBL] [Abstract][Full Text] [Related]
3. Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the IMAGE study.
Middleton MR; Dalle S; Claveau J; Mut P; Hallmeyer S; Plantin P; Highley M; Kotapati S; Le TK; Brokaw J; Abernethy AP
Cancer Med; 2016 Jul; 5(7):1436-43. PubMed ID: 27118102
[TBL] [Abstract][Full Text] [Related]
4. Real-world evidence for option value in metastatic melanoma.
Wong WB; To TM; Li M; Lee W; Veenstra DL; Garrison LP
J Manag Care Spec Pharm; 2021 Nov; 27(11):1546-1555. PubMed ID: 34431715
[No Abstract] [Full Text] [Related]
5. Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).
Forschner A; Eichner F; Amaral T; Keim U; Garbe C; Eigentler TK
J Cancer Res Clin Oncol; 2017 Mar; 143(3):533-540. PubMed ID: 27878363
[TBL] [Abstract][Full Text] [Related]
6. Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
Dalle S; Mortier L; Corrie P; Lotem M; Board R; Arance AM; Meiss F; Terheyden P; Gutzmer R; Buysse B; Oh K; Brokaw J; Le TK; Mathias SD; Scotto J; Lord-Bessen J; Moshyk A; Kotapati S; Middleton MR
BMC Cancer; 2021 May; 21(1):642. PubMed ID: 34051732
[TBL] [Abstract][Full Text] [Related]
7. A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
Drysdale E; Peng Y; Nguyen P; Baetz T; Hanna TP
Melanoma Res; 2019 Dec; 29(6):635-642. PubMed ID: 30789386
[TBL] [Abstract][Full Text] [Related]
8. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.
Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Wysoczański W; Matusewicz W; Kozłowska-Wojciechowska M
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2087-2094. PubMed ID: 28608286
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization.
Lu B; Dai WF; Croxford R; Isaranuwatchai W; Beca J; Menjak IB; Petrella TM; Mittmann N; Earle CC; Gavura S; Mercer RE; Hanna TP; Chan KKW
Cancer Med; 2023 May; 12(10):11451-11461. PubMed ID: 36999965
[TBL] [Abstract][Full Text] [Related]
10. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
11. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
12. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
[TBL] [Abstract][Full Text] [Related]
13. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma.
Gibson EJ; Begum N; Koblbauer I; Dranitsaris G; Liew D; McEwan P; Yuan Y; Juarez-Garcia A; Tyas D; Pritchard C
J Med Econ; 2019 Jun; 22(6):531-544. PubMed ID: 30638416
[No Abstract] [Full Text] [Related]
14. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.
Mohr P; Ascierto P; Arance A; McArthur G; Hernaez A; Kaskel P; Shinde R; Stevinson K
J Eur Acad Dermatol Venereol; 2018 Jun; 32(6):962-971. PubMed ID: 29044660
[TBL] [Abstract][Full Text] [Related]
15.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
17. Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.
Jochems A; Leeneman B; Franken MG; Schouwenburg MG; Aarts MJB; van Akkooi ACJ; van den Berkmortel FWPJ; van den Eertwegh AJM; Groenewegen G; de Groot JWB; Haanen JBAG; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WHJ; Louwman MWJ; Piersma D; van Rijn RS; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; Uyl-de Groot CA; van der Hoeven KJM
Anticancer Drugs; 2018 Jul; 29(6):572-578. PubMed ID: 29659371
[TBL] [Abstract][Full Text] [Related]
18. Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis.
Rigo R; Doherty J; Koczka K; Kong S; Ding PQ; Cheng T; Cheung WY; Monzon JG
Curr Oncol; 2021 Oct; 28(5):3978-3986. PubMed ID: 34677256
[TBL] [Abstract][Full Text] [Related]
19. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
20. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]